Tradingview 2026

• NanoViricides has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 Oral Gummies. • The trial is being conducted under the leadership of Professor Katoto, with Patrick, a Fogarty Fellow and member of the Institute for Health Metrics, involved in the process. • This development is significant as it advances the testing of NV-387, moving the drug candidate closer to potential commercialization and clinical use.

• India's capital goods companies faced a challenging April-June quarter, experiencing significant pressure on both profit margins and overall earnings. • Renu Baid of IIFL Institutional Equities views this weakness as temporary, citing encouraging order books and a positive long-term outlook. • Baid predicts a 40-45% revenue CAGR and 45-50% earnings growth over the next two years, with margins stabilizing between 14.5% and 15%.

• Thursday's Q1 earnings reports revealed a mixed financial landscape characterized by strong domestic demand offset by overseas pressures. • Tata Motors faced challenges due to a weaker performance from Jaguar Land Rover (JLR), whereas LG Electronics and Honasa Consumer reported strong quarterly results. • These divergent outcomes highlight the varying impact of global economic headwinds on different business sectors.